Seroprevalence of SARS‐CoV‐2‐specific antibodies in Sydney after the first epidemic wave of 2020
Field | Value | Language |
dc.contributor.author | Gidding, Heather F | en_AU |
dc.contributor.author | Machalek, Dorothy A | en_AU |
dc.contributor.author | Hendry, Alexandra J | en_AU |
dc.contributor.author | Quinn, Helen E | en_AU |
dc.contributor.author | Vette, Kaitlyn | en_AU |
dc.contributor.author | Beard, Frank H | en_AU |
dc.contributor.author | Shilling, Hannah S | en_AU |
dc.contributor.author | Hirani, Rena | en_AU |
dc.contributor.author | Gosbell, Iain B | en_AU |
dc.contributor.author | Irving, David O | en_AU |
dc.contributor.author | Hueston, Linda | en_AU |
dc.contributor.author | Downes, Marnie | en_AU |
dc.contributor.author | Carlin, John B | en_AU |
dc.contributor.author | O'Sullivan, Matthew VN | en_AU |
dc.contributor.author | Dwyer, Dominic E | en_AU |
dc.contributor.author | Kaldor, John M | en_AU |
dc.contributor.author | Macartney, Kristine | en_AU |
dc.date.accessioned | 2021-06-02T04:55:06Z | |
dc.date.available | 2021-06-02T04:55:06Z | |
dc.date.issued | 2021 | |
dc.identifier.uri | https://hdl.handle.net/2123/25244 | |
dc.description.abstract | OBJECTIVES: To estimate SARS-CoV-2-specific antibody seroprevalence after the first epidemic wave of coronavirus disease 2019 (COVID-19) in Sydney. SETTING, PARTICIPANTS: People of any age who had provided blood for testing at selected diagnostic pathology services (general pathology); pregnant women aged 20-39 years who had received routine antenatal screening; and Australian Red Cross Lifeblood plasmapheresis donors aged 20-69 years. DESIGN: Cross-sectional study; testing of de-identified residual blood specimens collected during 20 April - 2 June 2020. MAIN OUTCOME MEASURE: Estimated proportions of people seropositive for anti-SARS-CoV-2-specific IgG, adjusted for test sensitivity and specificity. RESULTS: Thirty-eight of 5339 specimens were IgG-positive (general pathology, 19 of 3231; antenatal screening, 7 of 560; plasmapheresis donors, 12 of 1548); there were no clear patterns by age group, sex, or location of residence. Adjusted estimated seroprevalence among people who had had general pathology blood tests (all ages) was 0.15% (95% credible interval [CrI], 0.04-0.41%), and 0.29% (95% CrI, 0.04-0.75%) for plasmapheresis donors (20-69 years). Among 20-39-year-old people, the age group common to all three collection groups, adjusted estimated seroprevalence was 0.24% (95% CrI, 0.04-0.80%) for the general pathology group, 0.79% (95% CrI, 0.04-1.88%) for the antenatal screening group, and 0.69% (95% CrI, 0.04-1.59%) for plasmapheresis donors. CONCLUSIONS: Estimated SARS-CoV-2 seroprevalence was below 1%, indicating that community transmission was low during the first COVID-19 epidemic wave in Sydney. These findings suggest that early control of the spread of COVID-19 was successful, but efforts to reduce further transmission remain important. | en_AU |
dc.language.iso | en | en_AU |
dc.subject | COVID-19 | en_AU |
dc.subject | Coronavirus | en_AU |
dc.title | Seroprevalence of SARS‐CoV‐2‐specific antibodies in Sydney after the first epidemic wave of 2020 | en_AU |
dc.type | Article | en_AU |
dc.identifier.doi | 10.5694/mja2.50940 | |
dc.relation.other | New South Wales Department of Health | en_AU |
dc.relation.other | National Health and Medical Research Council | en_AU |
dc.relation.other | Children's Hospital at Westmead | en_AU |
Associated file/s
There are no files associated with this item.
Associated collections